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Dengue viruses (DENV) are the most important mosquito transmitted viral pathogens
infecting humans. DENV infection produces a spectrum of disease, most commonly caus-
ing a self-limiting ﬂu-like illness known as dengue fever; yet with increased frequency,
manifesting as life-threatening dengue hemorrhagic fever (DHF). Waning cross-protective
immunity from any of the four dengue serotypes may enhance subsequent infection with
another heterologous serotype to increase the probability of DHF. Decades of effort to
develop dengue vaccines are reaching the ﬁnishing line with multiple candidates in clini-
cal trials. Nevertheless, concerns remain that imbalanced immunity, due to the prolonged
prime-boost schedules currently used in clinical trials, could leave some vaccinees tem-
porarily unprotected or with increased susceptibility to enhanced disease. Here we develop
a DENV serotype 1 (DENV-1) DNA vaccine with the immunodominant cross-reactive B cell
epitopes associated with immune enhancement removed. We compare wild-type (WT)
with this cross-reactivity reduced (CRR) vaccine and demonstrate that both vaccines are
equally protective against lethal homologous DENV-1 challenge. Under conditions mimick-
ing natural exposure prior to acquiring protective immunity,WT vaccinated mice enhanced
a normally sub-lethal heterologous DENV-2 infection resulting in DHF-like disease and 95%
mortality in AG129 mice. However, CRR vaccinated mice exhibited redirected serotype-
speciﬁc and protective immunity, and signiﬁcantly reduced morbidity and mortality not
differing from naïve mice. Thus, we demonstrate in an in vivo DENV disease model,
that non-protective vaccine-induced immunity can prime vaccinees for enhanced DHF-
like disease and that CRR DNA immunization signiﬁcantly reduces this potential vaccine
safety concern. The sculpting of immune memory by the modiﬁed vaccine and result-
ing redirection of humoral immunity provide insight into DENV vaccine-induced immune
responses.
Keywords: dengue, dengue vaccines, DNA vaccines, immune refocusing, vaccine safety, antibody-dependent
enhancement, original antigenic sin, dengue hemorrhagic fever
INTRODUCTION
Dengue viruses (DENV) are the most prevalent arthropod-borne
viral pathogens infecting humans. These mosquito-transmitted
viruses, members of the Flaviviridae, are endemic in most tropical
and sub-tropical countries with nearly half of the world’s popula-
tion living at risk of DENV infection and resulting in over amillion
estimated infections annually (Gubler, 2002; Mackenzie et al.,
2004). InfectionwithDENVcan cause a broad range of symptoms,
ranging from subclinical, to the self-limiting ﬂu-like illness dengue
fever, to the more severe and life-threatening dengue hemorrhagic
fever and shock syndrome (DHF/DSS), characterized by increased
vascular permeability producing plasma leakage, severe thrombo-
cytopenia and hypotension leading to circulatory collapse (Gubler,
2006). DENV prevalence, infection rates, and disease severity have
increased exponentially since the middle of the last century (Guz-
man et al., 2010). Despite decades of interest, need, and effort there
remains no available dengue vaccine (Guy et al., 2010; Miller, 2010;
Murphy and Whitehead, 2011; Thomas, 2011).
Dengue vaccine development faces both biological and
immunological challenges. These include the necessity for amulti-
valent vaccine inducing balanced immunity, the lack of an animal
model for DENVdisease, and concerns regarding vaccine-induced
immunopathology (Murphy and Whitehead, 2011; Heinz and
Stiasny, 2012). DENV immune responses are both protective
and pathogenic and this duality challenges vaccine development
(Rothman, 2004). There are four closely related yet phyloge-
netically distinct DENV serotypes (DENV-1, -2, -3, and -4)
and infection with any one serotype appears to induce life-
long serotype-speciﬁc immunity yet cross-protection between
serotypes is limited and transient (Sabin, 1952; Kuno, 2003).
Thus, in endemic regions individuals may be susceptible to up
to four different DENV infections. Although there are a num-
ber of risk factors associated with DHF such as virus and host
genetics, the strongest risk factor for severe dengue pathology is
secondary infection with a previously unencountered (heterolo-
gous) serotype (Murphy and Whitehead, 2011). This association
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explains the exponential increase of DHF/DSS in recent decades as
co-circulation and simultaneous transmission of the four DENV
serotypes increases both temporally and geographically (Macken-
zie et al., 2004; Gubler, 2006; Guzman et al., 2010). In humans,
increasing viral load correlates with DENV disease severity and
a large body of evidence points to the importance of immune
enhancement being a causal factor for the increased viral loads
associated with DHF (Vaughn et al., 2000; Libraty et al., 2002).
Twodistinct yet notmutually exclusivemechanisms of immune
enhancement explain the pathogenic manifestations characteriz-
ing DHF/DSS. The leading hypothesis is that DHF occurs via
antibody-dependent enhancement (ADE) of infection, a phe-
nomenon originally described for ﬂaviviruses but later found
to occur with diverse pathogens (Hawkes, 1964; Halstead, 1989;
Morens, 1994; Thomas et al., 2006). Preexisting cross-reactive
antibodies from a previous infection (or maternal antibodies in
infants) recognize and bind to heterologous virus in a secondary
infection (primary infection in infants), yet are unable to neutral-
ize this virus, either because they are non-neutralizing, or for a lack
of sufﬁcient avidity or occupancy (Pierson et al., 2008). However,
these non-neutralizing antibody–virus complexes increase the
infection of monocytes via their Fc receptors, dramatically increas-
ing viral replication and load, thereby causing DHF. Weakly- and
non-neutralizing cross-reactive antibodies induced from immun-
odominant B cell epitopes are known to comprise the majority
of the humoral immune response to DENV infection (Lai et al.,
2008; Crill et al., 2009). In a recently developed type I/type II
IFN receptor knock-out mouse model (AG129) of DENV dis-
ease (Williams et al., 2009), sub-neutralizing levels of homologous
or heterologous DENV immune mouse sera (Balsitis et al., 2010;
Zellweger et al., 2010) or cross-reactive human monoclonal anti-
bodies (MAbs; Beltramello et al., 2010) enhanced viral replication
in vivo producing a DHF-like disease.
The second, related mechanism of immune enhanced DENV
pathology, also a generalized phenomenon, posits that there is
a highly skewed cellular response to heterologous DENV infec-
tion driven by low afﬁnity, cross-reactive memory CD4+ and
CD8+ T cells (Brehm et al., 2002; Welsh and Selin, 2002; Welsh
et al., 2004). Cross-reactive T cell epitopes have been identiﬁed
across the DENV proteome, however, immunodominant CD8+
T cell epitopes in non-structural protein NS3 appear to be those
most strongly associated with DHF (Mathew and Rothman, 2008;
Duangchinda et al., 2010; Friberg et al., 2011).
The common theme throughout DENV immune enhancement
is the concept of “original antigenic sin”describing a phenomenon
ﬁrst observed in response to inﬂuenza, it has since been found
to be common across diverse taxa (Francis, 1953; Welsh and
Fujinami, 2007). Original antigenic sin describes the shift in
the immunodominance hierarchy that occurs when prior expo-
sure to cross-reactive antigens alters and inhibits subsequent
immune response to related antigens, either in new infections
or through vaccination (Brehm et al., 2002). Both humoral and
cellular responses can be plagued by such misdirected or inappro-
priate heterotypic immunity (Welsh and Fujinami, 2007). The
phenomenon is most severe when the cross-reactive antigenic
responses are immunodominant as is the case with both cellu-
lar and humoral DENV immunity. Thus, for DENV, not only
does original antigenic sin appear to play an important role in the
more severe DENV pathologies but it also creates a potential vac-
cine safety issue as a lack of protective tetravalent vaccine-induced
immunity could prime vaccinees for DHF upon subsequent infec-
tion (Durbin andWhitehead, 2011; Murphy andWhitehead, 2011;
Schmitz et al., 2011; Heinz and Stiasny, 2012).
Concerns for dengue vaccination priming individuals for
severe disease via immune enhancement have necessitated that
dengue vaccines must produce balanced, tetravalent, and pro-
tective immunity, optimally derived from a single dose vacci-
nation providing long-lasting protection (Miller, 2010; Murphy
and Whitehead, 2011; Heinz and Stiasny, 2012). Inducing bal-
anced and protective immunity has been the biggest hurdle
in DENV vaccination (Sun et al., 2009; Morrison et al., 2010;
Durbin and Whitehead, 2011). Tetravalent live-attenuated vac-
cines are susceptible to replication interference between different
vaccine viruses (Guy et al., 2009) requiring multiple boosts spread
over 6–12 months (Sin Leo et al., 2012). Nevertheless, multiple
live-attenuated DENV vaccines are advancing in human clini-
cal trials and promising results suggest potential licensure this
decade (Durbin and Whitehead, 2009; Guy et al., 2011; Heinz and
Stiasny, 2012).
We have developed a second generation ﬂavivirus vaccine plat-
form attempting to address some of the potential obstacles to
DENV vaccine development. The DNA vaccine platform con-
sists of an expression plasmid containing only the envelope (E,
the primary protective antigen) and premembrane (prM) struc-
tural protein genes. Upon uptake by host cells the structural
genes are transcribed and translated and the proteins self-assemble
into virus-like particles (VLPs) presenting authentic E proteins
(Chang et al., 2001, 2003). Our wild-type (WT) ﬂavivirus DNA
vaccines are demonstrably safe, immunogenic, and protective
against Japanese encephalitis, West Nile, and dengue viruses in
both non-human animals (Davis et al., 2001; Chang et al., 2003,
2007; Hughes et al., 2012b) and in humans (Martin et al., 2007).
DNA vaccines stimulate strong CD4+ T cell responses as do inac-
tivated and subunit vaccines and yet also strongly stimulate CD8+
T cell responses similar to live-attenuated vaccines (Laylor et al.,
1999; Martin et al., 2007). Because VLPs lack infectious RNA and
are non-replicating, multivalent DNA vaccines are less susceptible
to replication interference than live-attenuated vaccines (Petersen
and Roehrig, 2007; Guy et al., 2009). Most importantly, DNA
vaccines can be readily manipulated and engineered to prime
speciﬁc epitopes and redirect immunity. This sculpted immune
memory priming can redirect subsequent vaccine boosts or natu-
ral exposure toward protective, DENV serotype-speciﬁc epitopes
increasing both vaccine safety and efﬁcacy (Miller, 2010; Nara
et al., 2011; Schmitz et al., 2011; Hughes et al., 2012a).
In this work we introduce substitutions into two distinct
E protein antigenic regions of a WT DENV-1 DNA vaccine
(pVD1-WT) ablating cross-reactive, immunodominant, weakly
or non-neutralizing B cell epitopes (Crill et al., 2009) associated
with immune enhancement, to limit the ability of this cross-
reactivity reduced vaccine (pVD1-CRR) to potentiate DHF via
ADE. We extend upon previous proof in principle work with
DENV-2 (Chang et al., 2003; Hughes et al., 2012a,b) to test pVD1-
CRR safety and efﬁcacy via active vaccination of AG129 mice.
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Both pVD1-WT and pVD1-CRR were equally protective against
lethal, homologous DENV-1 challenge. pVD1-CRR vaccinated
mice produced signiﬁcantly less antibody recognizing immun-
odominant enhancing epitopes, exhibited signiﬁcantly increased
serotype-speciﬁc and protective immunity in response to heterol-
ogous DENV-2 challenge, and were less susceptible to lethally
enhanced heterologous DENV-2 DHF-like disease. These results
provide new insights into sculpting humoral immunity that
should advance the development of DENV vaccines and our
understanding of the mechanisms of their protective efﬁcacy.
MATERIALS AND METHODS
VACCINE CONSTRUCTION, CHARACTERIZATION, AND PREPARATION
The construction of pVD1-WT and pVD1-CRR vaccine plas-
mids was the same as for DENV-2 DNA vaccine plasmids that
have been previously described in detail (Chang et al., 2003; Crill
et al., 2009). Brieﬂy, pVD1-WT was constructed using DENV-1
strain (BC94/95) for cDNA cloning of prM and 80% DENV-1 E
protein with the C-terminal 20% of E replaced with the homol-
ogous region of Japanese encephalitis virus (JEV). Eighty percent
DENV-1 E corresponds to the ectodomain and the C-terminal
20% corresponds to the helical stems (E-H1, E-H2) and trans-
membrane domain (TMD) anchor helices (E-T1, E-T2; Zhang
et al., 2003; Lin et al., 2011). The pVD1-WT and pVD1-CRR vac-
cines utilized in this study also contained a potent CD4+ T cell
epitope identiﬁed in West Nile virus (WNV) and located in the
TMD.The inclusion of this epitope into ourDENV-2DNAvaccine
(pVD2) and into pVD2-CRR was shown to boost the neutraliz-
ing antibody responses of vaccinated mice about twofold. The
identiﬁcation, construction, and characterization of this epitope
has recently been described in detail (Hughes et al., 2012b). Intro-
duction of the WNV TMD CD4+ epitope into pVD1 required
introducing four amino acid substitutions (V474I, A484T,
T488V, and V493L) into the C-terminal 20% JEV E sequence
of pVD1.
pVD1-CRR was constructed using the primers listed in Table 1
and pVD1-WT as the DNA template with Stratagene Quick
Change multi, site-directed mutagenesis kit (Stratagene, La Jolla,
CA) following the manufacturer’s recommended protocols. Struc-
tural gene regions and regulatory elements of all plasmids were
sequenced entirely upon identiﬁcation of the correct mutation.
ETHICS STATEMENT
All animal experiments were approved by the IACUC at the US
Centers for Disease Control and Prevention (CDC), Division of
Vector-borne Disease (DVBD); an AAALAC certiﬁed facility. Pro-
tocols followed theUSNationalGuidelines deﬁned in theGuide for
the Care andUse of LaboratoryAnimals, 8th edition, 2011,National
Academy Press.
MICE: PROTECTIVE EFFICACY
Type I/type II IFN receptor-knock-out mice (AG129) were
obtained from the DVBD, CDC colony. Six-week-old AG129 mice
(DVBD, n = 26) were immunized intramuscularly (i.m.) with
100 μg of pVD1-WT or pVD1-CRR vaccine (50 μg in each thigh)
at 0, 4, and 8 weeks and with naïve age-matched controls (n = 8),
were challenged at 12 weeks intraperitoneally (i.p.) with 1.1 × 105
focus forming units (FFU) of DENV-1 Mochizuki strain. Based
upon results from previous dose-titration experiments four ani-
mals from each vaccine treatment and two naïve mice were a
priori selected for sacriﬁce 3 and 8 days post challenge (DPC). Sick
animals reaching predetermined morbidity endpoints were anes-
thetized, total bloodwas collected via cardiac puncture, euthanized
and carcasses were frozen at −80◦C for subsequent analysis.
MICE: VACCINE SAFETY
Six-week-old AG129 mice (DVBD, n = 26) were immunized with
100 μg of either pVD1-WT or pVD1-CRR vaccine (50 μg in each
thigh, i.m.) at 0 weeks and with age-matched naïve mice (n = 10)
were i.p. challenged at 12 weeks with 4.2 × 105 FFU of DENV-
2 S221 (gift from S. Shresta; Zellweger et al., 2010). Four mice
from each vaccine treatment and two naïve mice were a priori
selected for sacriﬁce 3 DPC. Sick animals reaching predetermined
morbidity endpoints were anesthetized, total blood was collected
via cardiac puncture, euthanized, and necropsy was performed
with livers collected and stored in 10% formalin for histology.
HISTOLOGY
Liver tissue sections were prepared, stained, and analyzed by Todd
Bass at the Colorado State University (CSU) College of Veteri-
nary Medicine and Biomedical Sciences Histology Laboratories.
Hematoxylin and Eosin (H&E) staining and immunohistochem-
istry slides were interpreted by Dr. Barbara Powers at CSU and Dr.
Nord Zeidner (CDC) assisted with H&E slide interpretation and
Table 1 | Nucleotide sequences of mutagenic primers.
Primer Primer Sequence (5′-3′) Nucleotide substitution Amino acid substitution
D1-G106R TTCCTTTCCGAAGAGACGACAGCCATTGCCCCAGCC GGG-CGT Gly-Arg
D1-L107D TTCCTTTTCCGAAATCCCCACAGCCATTGCCCCAG CTC-GAT Leu-Asp
D1-G106RL107D CTTCCTTTTCCGAAATCCCGACAGCCATTGCCCCAGCC GGA-CGGCTC-GAT Gly-ArgLeu-Asp
D1-K310D AGCCACTTCGTCCTCTAGCTTGAATGAGCCTGTGC AAA-GAC Lys-Asp
D1-E311K TCAGCCACCTTTTTCTCTAGCTTGAATGAGCCTGTGC GAA-AAG Glu-Lys
D1-K310DE311K GGGTCTCAGCCACCTTGTCCTCTAGCTTGAATGAGCCTGTGC AAA-GACGAA-AAG Lys-AspGlu-Lys
D1-P364Q GCCTCAATGTTGACCTGTTTTTCTTTGTCAGTGACTATGGG CCA-CAG Pro-Gln
Mutated nucleotides are shown in bold.
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photography. IHC utilized Ventana Medical Systems ultraView
Universal Alkaline Phosphatase Red Detection Kit following the
manufacturer’s recommended protocols and a Benchmark Ultra
automated system. Pretreatment was with protease II for 6 min,
rabbit anti DENV-2 NS1 serum, generated at the CDC, was used
at a 1:20 dilution, and anti-rabbit secondary antibody was applied
for 12 min.
CHARACTERIZATION OF pVD1-CROSS-REACTIVITY REDUCED PLASMID
VACCINE EXPRESSED VIRUS-LIKE PARTICLE ANTIGEN
Antigen-capture ELISA (Ag-ELISA) was used to characterize
VLP antigen following previously described protocols (Crill et al.,
2009). Brieﬂy, VLP antigen was collected from mutagenized and
WTpVD1 transformedCOS-1 cells. Secreted antigenwas captured
in the inner 60 wells of Immulon II HB ﬂat-bottom 96-well plates
(Dynatech Industries, Inc., Chantilly, VA) with polyclonal rabbit
anti-DENV-1 WTVLP sera, incubated overnight at 4◦C, and wells
were blocked with 300 μl of StartBlock blocking buffer (Pierce,
Rockford, IL,USA) according to themanufacturer’s recommended
protocol. Antigen was diluted twofold in PBS, incubated for
2 h at 37◦C and detected with murine hyper-immune ascitic
ﬂuid (MHIAF) speciﬁc for DENV-2 diluted in 5% milk/PBS.
MHIAF was detected using horseradish peroxidase (HRP) conju-
gated goat anti-mouse IgG (Jackson ImmunoResearch,Westgrove,
PA) in 5% milk/PBS and incubated for 1 h at 37◦C. Bound
conjugate was detected with 3,3′5,5′-tetramethylbenzidine sub-
strate (TMB; Neogen Corp., Lexington, KY), the reaction was
stopped with 2N H2SO4 and measured atA450 using a Synergy HT
Multi-Detection Microplate Reader (Bio-Tek Instruments, Inc.,
Winooski, VA). WT and mutant antigens were screened against
the MAb panel using the same ELISA protocol as above with the
exception that twofold dilutions of the speciﬁc MAb replaced the
anti-DENV-2 MHIAF and antigens were used at a single stan-
dardized concentration producing an optical density (OD) of
1.0. Standardized concentrations of WT and mutant VLP anti-
gens were analyzed in Ag-ELISA to determine MAb endpoint
reactivities.
MONOCLONAL ANTIBODIES
MAbs 4G2, 6B6C-1, 4A1B-9, 1B7, D3-5C9-1, 1A1D-2, 9D12,
9A3D-8, 3H5, and D2-1F1-3 were obtained from hybridomas
in the collection of the Arboviral Diseases Branch, Division of
Vector-borne Diseases, Centers for Disease Control and Preven-
tion. Many of these MAbs originated from the work of John
Roehrig (Roehrig et al., 1998), 4G2, 5H3, 1B7, D3-5C9-1, 9D12,
3H5, and D2-1F1-3 hybridomas were originally obtained by the
CDC from the Walter Reed Army Institute (Henchal et al., 1985).
MAbs 23-1, 23-2, and 5-2 were provided by Dr. L.-K. Chen of Tzu
Chi University, Hualien, Taiwan. MAbs 10-D35A, 20-783-745014,
and MDVP-55A are commercially available and were purchased
from Fitzgerald Industries International, GenWay Biotech Inc.,
and Immunology Consultants Laboratory Inc. respectively.
EPITOPE-SPECIFIC IgG ELISA
We used DENV-1 and DENV-2 epitope-speciﬁc IgG ELISA (ES-
ELISA) to determine total DENV-1 or DENV-2 IgG endpoint
titers and to determine percent DENV-1 or DENV-2 EDIIFP and
non-EDIIFPEDIIICR epitope-speciﬁc IgG. The DENV-2 ES-ELISA
has been previously described (Crill et al., 2009; Hughes et al.,
2012a) and the DENV-1 ES-ELISA was similarly used with a
few modiﬁcations. Brieﬂy, Rabbit anti-pVD1 or pVD2 sera was
coated onto plates overnight at 4◦C. Standardized concentrations
of WT and CRR antigens were captured, AG129 mouse serum
was diluted two- to fourfold down the plate and detected with
goat anti-mouse IgG (Jackson ImmunoResearch). The DENV-
1 epitope-speciﬁc knock-out antigens utilized are described in
Table 2. OD450 values were modeled as non-linear functions of the
log10 serum dilutions using a non-linear sigmoidal dose-response
(variable slope) regression inGraphPadPrismversion 4.0 (Graph-
Pad Software, Inc. La Jolla, CA) and endpoint titrations were
determined as the titer where the OD450 value equaled two-times
the OD450 value of the test serum reacted against normal COS-1
antigen.
E protein structural domain II fusion peptide (EDIIFP)
and non-EDIIFP EDIII cross-reactive (EDIIFP EDIIICR) epitope-
speciﬁc IgG percentages were calculated as previously described
(Crill et al., 2009; Hughes et al., 2012a) with minor modiﬁcations.
The DENV-1 epitope-speciﬁc IgG percentages for all vaccinated
mice were calculated by dividing the IgG endpoint titer obtained
with each knock-out antigen (EDIIFP or EDIIFPEDIIICR) by the
endpoint titer obtained with pVD1-WT antigen on the same
sera, subtracting this value from 1.0, and multiplying by 100.
Speciﬁcally, EDIIFP epitope-speciﬁc percentages were calculated
as 100× [1.0-(DENV-1 EDIIFP antigen endpoint/ DENV-1 WT
antigen endpoint)]. Non-EDIIFPEDIIICR IgG proportions were
calculated as 100*(endpoint EDIIFPEDIIICR/endpoint WT) for
WT vaccinated mice and because pVD1-CRR vaccinated mouse
sera contain antibodies that do not recognize some WT antigen
epitopes (WT antigen acts as the knock-out antigen) but recognize
themodiﬁed epitopes of theCRRantigens, the pVD1-CRRantigen
(EDIIFPEDIIICR) replaced pVD1-WT antigen to determine 100%
E reactivity for pVD1-CRRvaccinatedmice and similarly, the non-
EDIIFPEDIIICR IgG proportion for pVD1-CRR immunized mice
was calculated as 100*(DENV-1 WT antigen endpoint/ DENV-
1 EDIIFPEDIIICR antigen endpoint). DENV-2 epitope-speciﬁc
IgG populations were similarly determined but used the previ-
ously described DENV-2 EDIIFP and EDIIFPEDIIICR knock-out
antigens to determine endpoints (Crill et al., 2009; Hughes et al.,
2012a) for both pVD1-WT and pVD1-CRR vaccinated sera. In
cases where the endpoint titer determined with a mutant antigen
was the same or greater than the endpoint titer obtained with the
cognate antigen we interpreted these cases as undetectable levels
of antibody recognizing the epitope of interest and the percent of
IgG was conservatively set at 1.0%. Calculated EDIIFP IgG end-
point titers were determined indirectly with the EDIIFP knock-out
and WT antigens by multiplying the total IgG endpoint titer by
the percent EDIIFP IgG.
EPITOPE-BLOCKING ELISA
Epitope blocking ELISA was utilized to determine the vaccinated
mouse response to well-characterized murine MAb epitopes. This
ELISA was set up similar to ES-ELISA in that plates were coated
overnight at 4◦C with rabbit anti-DENV-2 serum, blocked with
StartBlock (Pierce), dried and WT DENV-2 VLP antigen was
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captured 1 h at 37◦C. After washing, pVD1-WT or pVD1-CRR
vaccinated, DENV-2 challenged mouse serum (3 DPC, pooled for
each vaccine treatment due to limited availability of serum) was
diluted 1:40 in wash buffer and incubated 1hr at 37◦C. Following
pooled serum incubation and wash, 0.5 μg of MAb conjugated
with HRP was added to each well and incubated for 1 h at 37◦C
to compete with the already bound antibody from vaccinated
mouse serum for WT DENV-2 VLP antigen. Bound conjugate
was detected with TMB substrate and plates incubated for 10 min
prior to being stopped with H2SO4 and ODs were determined as
OD = OD of A450 − OD of A630. Percent blocking was deter-
mined by comparison to replicate wells with 0.5 μg HRP labeled
MAb competing against pre-adsorbed normal mouse serum using
the following calculation, 100–100*[(OD of vaccinated serum
on DENV-2 Ag−OD of vaccinated serum on normal Ag)/OD
of normal serum on DENV-2 Ag−OD of normal serum on
normal Ag)].
IN VITRO ANTIBODY-DEPENDENT ENHANCEMENT
Heat inactivated pVD1-WT and pVD1-CRR vaccinated mouse
sera (12 weeks post vaccination) were pooled into four groups
for each vaccine treatment, diluted, and titrated. Virus (DENV-
2 16681) was added to each dilution and incubated for 1 h at
37◦C. K562 cells (MOI = 0.5) were added to the antibody–
virus complexes and incubated 2 h. After infection, cells were
centrifuged, supernatants removed, resuspended in RPMI media
(10% FBS) and plated. DENV infection alone was used as virus
control.
FOCUS REDUCTION MICRO-NEUTRALIZATION ASSAY
Focus reduction micro-neutralization assay (FRμNT) assay was
utilized as previously described (Crill et al., 2009) with few
modiﬁcations. Vaccinated mouse sera were diluted 1:10, heat
inactivated, titrated twofold to the volume of 40 μL, and 320
virus FFU/40 μL (DENV-1 56BC94/95, DENV-2 16681, DENV-
3 116RC1396, or DENV-4 130) was added to each dilution.
FRμNT titers were calculated for each virus relative to a back
titration. Exact 50% of FRμNT titers were modeled using Graph
Pad Prism version 4 sigmoidal dose response (variable slope)
non-linear regression. Values are the average of two independent
replicates.
VIREMIA AND BRAIN VIRUS TITERS
Viremia was determined in a similar antigen-focus assay as
described for FRμNT except that no virus was added. Cells were
incubated, overlaid, acetone ﬁxed, immunostained, and counted
as described for FRμNT. Virus brain titers were determined from
previously frozen mouse carcasses. Brain tissue was aspirated with
a 3 mL syringe and 18 gage needle, weighed, and resuspended in
200 uL BA-1 media. Fifty microliters was used in the FRμNT as
described. FFU/g of tissue was back calculated from the aspirated
brain mass.
STATISTICAL ANALYSIS
Non-parametric analyses used the Mann–Whitney U test and
paired analyses utilized the paired t-test. All statistical analyses
were performed using GraphPad Prism 4.02.
RESULTS
VACCINE CONSTRUCTION
Based upon previously published and unpublished results with
DENV and other ﬂaviviruses (Crill and Chang, 2004; Sukupolvi-
Petty et al., 2007; Gromowski et al., 2008; Crill et al., 2009; Hughes
et al., 2012a), we introduced speciﬁc substitutions into cross-
reactive B cell epitopes of the envelope protein of aDENV-1 prM/E
expression plasmid (Chang et al., 2003) to generate a DENV-1
DNA vaccine candidate with reduced ability to induce the cross-
reactive antibodies that can be associated with ADE. The DENV-1
WT DNA vaccine (pVD1-WT) utilized as the template for the
CRR vaccine (pVD1-CRR) in this study was based upon previ-
ous studies with DENV-2 vaccines and contains a potent CD4+
epitope identiﬁed in WNV and demonstrated to increase the
immunogenicity of DENV-2 DNA vaccines (Hughes et al., 2012b).
We introduced substitutions into two important cross-reactive
regions of the DENV E protein, the highly conserved fusion pep-
tide of structural domain II (EDIIFP) and the A-strand and DE
loop of domain III (EDIII; Figure 1).
EDIIFP contains multiple overlapping immunodominant B
cell epitopes inducing broadly cross-reactive, weakly or non-
neutralizing antibodies associated with antibody-enhanced severe
DENV disease in both mice and humans (Stiasny et al., 2006;
Lai et al., 2008; Crill et al., 2009; Balsitis et al., 2010; Bel-
tramello et al., 2010; Zellweger et al., 2010). EDIII contains two
well-characterized overlapping antigenic regions, one stimulating
DENV complex cross-reactive antibodies varying in their neutral-
izing capabilities (Roehrig et al., 1998; Sukupolvi-Petty et al., 2007;
Gromowski et al., 2008; Cockburn et al., 2012) and the other stim-
ulating DENV serotype-speciﬁc, potently neutralizing antibodies
associated with DENV serotype-speciﬁc immunity (Gromowski
and Barrett, 2007; Sukupolvi-Petty et al., 2007; Crill et al., 2009;
Beltramello et al., 2010). We examined multiple substitutions at
EDIIFP residues G106 and L107 and at K310, E311, and P364 in
the cross-reactive antigenic region of EDIII (EDIIICR; Figure 1).
Final individual substitutions at these ﬁve residues were selected
based upon their inﬂuence on in vitro VLP secretion and their
effect on the reactivities of a panel of MAbs (Table 2).
EDIIFP substitutions tended to increase VLP secretion and
knocked-out the reactivity of ﬂavivirus group and sub-group
cross-reactive MAbs. EDIIICR substitutions tended to reduce VLP
secretion relative to WT and ablated the reactivity predominately
of DENV sub-complex cross-reactive MAbs. EDIIICR substitu-
tions were speciﬁcally selected not to interfere with the binding of
potently neutralizing EDIII lateral ridge serotype-speciﬁc MAbs.
Although human MAbs recognizing similar epitopes have been
identiﬁed, a growing body of evidence suggests they may not
comprise the main antigenic targets of the human neutralizing
antibody response (Beltramello et al., 2010; Dejnirattisai et al.,
2010; de Alwis et al., 2011; Wahala et al., 2012). The ﬁnal pVD1-
CRR plasmid, containing substitutions at all ﬁve of the sites
across both EDIIFP and EDIIICR antigenic regions (Figure 1),
knocked-out or reduced the reactivity to below detectable levels
of 11 cross-reactive monoclonal antibodies in our panel (Table 2).
The cross-reactive MAbs whose reactivities were not signiﬁcantly
reduced were 1B7, a sub-group cross-reactive MAb that neu-
tralizes all four DENV serotypes, and 10-D35A and D3-5C9-1,
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FIGURE 1 | Structural locations of the pVD1-CRR envelope (E) protein
cross-reactive epitope knock out substitutions.The locations of the
DENV-1 E substitutions introduced to construct pVD1-CRR mapped on the
crystal structure of the homologous DENV-2 E protein dimer (Modis et al.,
2003). (A) Locations of pVD1-CRR substitutions (spheres) on a ribbon diagram
of the mature E dimer as it appears looking straight down toward the virion
surface. The three structural domains are labeled and colored red for E
domain I (EDI), yellow for EDII, and blue for EDIII. The EDII fusion peptide
(EDIIFP) is also labeled and colored green. The glycans in EDI (N67) and EDII
(N153) are depicted as stick representations and colored brown. (B) Side view
of the E protein dimer with all colorations the same as in panel A. (C) Close
up of the EDIIFP from one monomer and EDIII region of the other at the
dimer interface, as it appears in panel B. The side chains of two residues in
the EDIIFP and three residues in EDIII where CRR substitutions were
introduced are depicted as ball and stick representations and labeled with the
introduced substitutions. Structural domains are colored as in panel A and the
two antigenic regions EDIIFP and EDIIICR are noted with circles roughly
representing the size of an IgG footprint binding to these regions.
weakly (for DENV-2 only) and non-neutralizing DENV complex
cross-reactive MAbs respectively.
PROTECTIVE EFFICACY
Both pVD1-WT and pVD1-CRR vaccines induce similarly high titer
IgG and protect mice from lethal DENV-1 challenge
To test for vaccine protective efﬁcacy we compared WT and CRR
DENV-1 DNA vaccines by immunizing groups of AG129 mice
(n = 26) and subsequently challenging with a lethal dose of
homologous DENV-1 (Mochizuki strain). AG129 type I/type II
IFN receptor knock-out mice have impaired neutralizing anti-
body responses (Schijns et al., 1994) and as expected our DNA
vaccines were not as immunogenic in these mice as in immuno-
competent mouse strains (data not shown). We therefore altered
our standard immunization schedule from a single 100 μg
boost 4 weeks following primary vaccination (100 μg) to two
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100 μg boosts at 4 and 8 weeks. This schedule elicited IgG
immune responses approaching the magnitude of those previ-
ously observed in other mouse strains with the two dose schedule
(Chang et al., 2003; Hughes et al., 2012a,b). Mice were challenged
at 12 weeks. Prior to challenge, mouse sera was collected to
measure vaccine-induced humoral immune responses. We used
ES-ELISA (Crill et al., 2009) to determine total DENV-1 IgG and
DENV-1 EDIIFP IgG. Total DENV-1 IgG endpoint titers were sim-
ilar between the two vaccines and averaged 7.7 × 104 ± 1.5 × 104
and 7.5 × 104 ± 1.8 × 104 for pVD1-WT and pVD1-CRR
immunized mice respectively (p = 0.524; Figure 2A). However,
pVD1-CRR immunized mice had signiﬁcantly lower proportions
of EDIIFP IgG than did pVD1-WT immunized mice, averaging
2.1 ± 0.96 and 33 ± 6.4% of the total IgG response respectively
(p = 0.0005, Figure 2B). Only two pVD1-CRR immunized mice
had measurable EDIIFP IgG (4.8 and 22%) with the remaining
mice being below detectable levels (conservatively set to 1.0% for
statistical analyses and EDIIFP IgG titer calculations). The pro-
portion of EDIIFP IgG for WT immunized mice was large and
variable, ranging from 0.8 to 73%, similar to that observed in
DENV infected humans (Stiasny et al., 2006; Crill et al., 2009;
Beltramello et al., 2010). Calculated EDIIFP IgG endpoint titers
averaged 2.0 × 104 ± 4.6 × 103 and 1.1 × 103 ± 3.4 × 102
for WT and CRR immunized mice respectively (p = 0.0001,
Figure 2C). Fifty percent neutralization (Nt50) titers, measured
by FRμNT, averaged 91.1 and 48.8 for pVD1-WT and pVD1-
CRR vaccinated mice respectively (p = 0.0047; Figure 2D). The
lower Nt50 titer for pVD1-CRR immunized mice was likely due
to reduced induction of EDIIICR antibodies recognizing epi-
topes similar to those of neutralizing MAbs 1A1D-2 and 9D12
that lost all measurable reactivity for the pVD1-CRR tissue cul-
ture derived VLPs (Table 1). These results suggest that targeted
FIGURE 2 | Protective Efficacy: Both pVD1-WT and pVD1-CRR
vaccines protect AG129 mice against lethal DENV-1 challenge. (A–D) 12
week post vaccination immunogenicity of AG129 mice immunized (i.m.)
with 100 μg of pVD1-WT or pVD1-CRR vaccines at 0, 4, and 8 weeks.
Geometric means and 95% conﬁdence intervals are depicted unless
otherwise noted. All endpoint titers were log10 transformed and statistical
signiﬁcance was determined using the Mann–Whitney U test to account for
non-normality of some transformed data. Panels B and C both used a
one-tailed test since there was an a priori expectation that pVD1-CRR
immunized mice would exhibit reduced EDIIFP recognizing IgG. (A) DENV-1
total IgG endpoint titers 12 weeks post immunization. (B) Percent of total
DENV-1 IgG recognizing immunodominant EDIIFP epitopes, arithmetic means
and 95% CI depicted. (C) Calculated DENV-1 EDIIFP IgG endpoint titers.
(D) DENV-1 50% antigen focus-reduction micro neutralization titers
(FRμNT50). A t test was utilized here as both data sets were normally
distributed. (E) pVD1-WT and pVD1-CRR immunized AG129 mice were
challenged with 1.1x105 FFU of DENV-1 (Mochizuki strain, i.p.) at 12 weeks.
Kaplan–Meier survival curves are shown. Both pVD1-WT (n = 18) and
pVD1-CRR (n = 18) vaccinated animals had the same survival (94%), which
was highly signiﬁcant in comparison to naïve mice (n = 4, p = 0.0003).
(F) Four mice from each vaccine treatment (not included in the survival
curves) were a priori scheduled to be euthanized 3 and 8 DPC. DENV-1
titers (FFU/mL) were log10 transformed and analyzed using two-way ANOVA;
error bars represent standard error of the mean (SEM). Vaccine treatment
was highly signiﬁcant (p < 0.0001). Bonferroni post hoc tests indicated
that viremia of each vaccinated group was signiﬁcantly lower than for naïve
mice (n = 2) 3 DPC (p < 0.001), only pVD1-CRR vaccinated mouse viremia
was signiﬁcantly lower than naïve mice (n = 2) 8 DPC (p < 0.01) and
there was no difference between WT or CRR vaccinated mouse viremia
3 or 8 DPC.
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substitution within EDIIFP can reduce the immunodominance of
this region.
Age-matched naïve (18-week-old, n = 8), pVD1-WT and
pVD1-CRR (n= 26 each) vaccinated animalswere challengedwith
1.1 × 105 FFU of the mouse-brain adapted DENV-1 Mochizuki
strain. This dose was>100 LD50 for 6–8-week-old mice (data not
shown). All immunized mice except a single animal from each
vaccine treatment were protected and survived challenge (94%
survival) which was highly signiﬁcant in comparison to naïve
mice (25% survival, p = 0.0003; Figure 2E). Time to death of
naïve mice ranged from 8 to 17 DPC and averaged 11.7 DPC;
the single vaccinated animals died 7 and 8 DPC for WT and
CRR vaccine treatments respectively. Surviving mice showed no
signs of sickness. Although DENV-1 Mochizuki is a mouse-brain
adapted virus, we observed limited neurological symptoms such
as paralysis in terminally sick mice and most exhibited hunched
and rufﬂed posture, lethargy, and a lack of interest in food and
water leading to weight loss prior to being euthanized. Four mice
from each vaccine treatment and two naïve mice were sched-
uled a priori to be euthanized at 3 DPC, a time point prior to
any outward sign of disease, and 8 DPC, a few days after the
initial signs of morbidity and mortality. Vaccinated mice exhib-
ited 100-fold and 10-fold lower viremia 3 and 8 DPC respectively,
compared to naïve controls; yet there was no difference in mean
viremic titers between WT or CRR vaccinated mice at either time
point (Figure 2F). A two-way ANOVA found vaccine treatment
to be highly signiﬁcant (p < 0.0001) and to account for 68% of
the variation. Bonferroni post hoc tests indicated that viremia
of each vaccinated group was signiﬁcantly lower than for naïve
mice 3 DPC (p < 0.001) whereas only pVD1-CRR immunized
mouse viremia was signiﬁcantly lower than naïve mice 8 DPC
(p < 0.01).
Because DENV-1 Mochizuki strain is a mouse-brain adapted
virus, we also determined virus titers of mouse-brain
homogenates. Brains fromboth naïve and vaccinatedmice were all
negative 3 DPC (<50 FFU/g brain tissue). By 8 DPC, the DENV-1
titer of naïve mouse-brain tissue was 100–1000 times greater than
for vaccinated mice. Of note, we only had tissue from a single 8
DPC naïve mouse-brain precluding rigorous statistical analysis.
Nevertheless, the single 8 DPC naïve mouse-brain virus titer was
2.3 × 104 FFU/g, geometric mean titers of WT and CRR vacci-
nated mice (n = 4 each) were 201 and 731 FFU/g of brain tissue
respectively with three WT and two CRR vaccinated titers below
the limits of assay detection (<50 FFU/g tissue). There was no dif-
ference in titer between WT and CRR vaccinated mouse-brains as
determined by t-test orMann–WhitneyU test (data not shown). A
Wilcoxon signed-rank test comparing all eight vaccinated mouse-
brain titers to the 2.3 × 104 titer for the naïve mouse-brain tissue
strongly rejected the null hypothesis of no difference (p = 0.0059),
suggesting that there was less virus in vaccinated compared to
naïve mouse brains 8 DPC.
Consistent with an anamnestic response to DENV-1 challenge,
both WT and CRR immunized surviving mice exhibited similar
order of magnitude increases in Nt50 titer 28 DPC (GMT = 690,
95% CI 504–944 and =362, 95% CI 218–601 for WT and
CRR respectively). Together, these data suggest that pVD1-WT
and pVD1-CRR vaccines are similarly immunogenic and able to
induce protective immunity against lethal homologous DENV-1
challenge in the AG129 DENV vaccine model.
VACCINE SAFETY: CROSS-REACTIVE REDUCED VACCINE REDIRECTS
IMMUNITY FROM IMMUNODOMINANT PATHOLOGICAL TOWARD
PROTECTIVE RESPONSES
Groups of AG129 mice (n = 26) were immunized with a single
100μgdose of pVD1-WTorpVD1-CRRvaccine and subsequently
challenged with a sub-lethal dose of heterologous DENV-2 S221
12 weeks post vaccination, the same timeline used for the homol-
ogous DENV-1 protective efﬁcacy challenge above. DENV-2 S221
is a mouse adapted isolate of Taiwanese strain PLO46 (Shresta
et al., 2006) capable of producing lethal hemorrhagic disease in
AG129 mice – similar to that observed in human DHF – via
ADE when sub-protective levels of DENV immune sera are pas-
sively transferred to mice subsequently challenged with non-lethal
doses of DENV-2 S221 (Balsitis et al., 2010; Zellweger et al., 2010).
We hypothesized that pVD1-WT immunized mice would be sus-
ceptible to antibody-enhanced DENV disease due to high levels
of vaccine-induced cross-reactive antibodies and that upon het-
erologous challenge; antibodies recognizing these epitopes would
be stimulated anamnestically. Conversely, pVD1-CRR vaccinated
mice should lack such cross-reactive antibody priming and sec-
ondary responses, be less susceptible to antibody enhanced viral
replication, and exhibit increased survival.
DENV-1 CRR vaccinated mice have reduced levels of
immunodominant EDIIFP IgG and reduced dengue disease
mortality compared to DENV-1 WT vaccinated mice
following DENV-2 challenge
To assess if pVD1-WT and -CRR vaccines induce different
antibody repertoires in vaccinated mice we collected 12-week
post-vaccination sera and utilized ES-ELISA (Crill et al., 2009)
to determine vaccine induced DENV-1 IgG titers and the propor-
tions and titers of IgG recognizing EDIIFP epitopes (Figure 1).
There was no difference in total DENV-1 IgG GMT between
pVD1-WT (3168, 95% CI 1792–5600; n = 20) and pVD1-CRR
immunized mice (1429, 95% CI 621–3289, n = 23; p = 0.128,
two-tailedMann–WhitneyU test; Figure 3A). The percent of total
DENV-1 IgG recognizing EDIIFP epitopes averaged 17.7 ± 4.6%
and 2.56 ± 1.2% for pVD1-WT and pVD1-CRR immunized
mice respectively (p = 0.0009). Again, only two CRR immunized
mice had detectable levels of EDIIFP IgG (9.4% and 21%) with
all remaining mice having no measurable EDIIFP IgG (=1.0%
for statistical analyses; Figure 3B). The calculated DENV-1 IgG
GMT recognizing EDIIFP epitopes was signiﬁcantly lower for
CRR (38.6, 95% CI 19.4–76.9) than for WT immunized mice
(272, 95% CI 97.2–760, p = 0.0023, one-tailed Mann–Whitney
U test; Figure 3C). These results again suggest that pVD1-
WT and pVD1-CRR vaccines are similarly immunogenic overall,
but that the pVD1-CRR vaccine induces less IgG recognizing
immunodominant EDIIFP epitopes.
Age-matched naïve (n = 10), pVD1-WT, and pVD1-CRR
(n = 26 each) immunized mice were challenged (i.p.) with a
sub-lethal dose (4.2 × 105 FFU) of DENV-2 S221 12 weeks fol-
lowing immunization for vaccine treatment groups. All naïvemice
survived DENV-2 challenge, though they did exhibit signs of
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FIGURE 3 | DENV-1 CRR vaccine stimulates reduced levels of
immunodominant cross-reactive EDIIFP IgG and reduces enhanced
DENV-2 mortality. (A–C) 12 week post vaccination immunogenicity of AG129
mice immunized (i.m.) with 100 μg of pVD1-WT or pVD1-CRR vaccines.
Geometric means and 95% conﬁdence intervals are depicted. Endpoint titers
were log10 transformed and statistical signiﬁcance was determined using the
two-tailed Mann–Whitney U test. Panels B and C both used a one-tailed test
since there was an a priori expectation that pVD1-CRR immunized mice
would exhibit reduced EDIIFP recognizing IgG. (A) DENV-1 total IgG endpoint
titers 12 weeks post immunization. (B) Percent of total DENV-1 IgG
recognizing immunodominant EDIIFP epitopes, arithmetic means and 95% CI
depicted. (C) Calculated DENV-1 EDIIFP IgG endpoint titers. (D) Survival of
pVD1-WT and pVD1-CRR immunized AG129 mice following sub-lethal
heterologous DENV-2 challenge. 12 weeks following vaccination, immunized
mice (n = 22) or age matched naïve controls (n = 8) were challenged (i.p.)
with 4.2 × 105 FFU of DENV-2 S221. Kaplan-Meier survival curves and p
values are shown. All naïve mice survived virus challenge with minimal
signs of morbidity, pVD1-WT vaccinated mice suffered 95% mortality from
enhanced DENV-2 disease (p < 0.0001, compared to naive). pVD1-CRR
immunized mice exhibited 68% survival which did not differ from naïve
mouse survival (100%, p = 0.0769) yet was signiﬁcantly greater than
pVD1-WT immunized mouse survival (4.5%, p < 0.0001). The Bonferroni
multiple comparison adjusted α = 0.017. (E) pVD1-CRR vaccinated
mice exhibited a rapid, large magnitude increase in DENV-2 neutralizing
antibody titers following DENV-2 challenge. FRμNT50 titers determined
with DENV-2 16681 virus on Vero cells, log10 transformed and the
transformed data analyzed by two-way ANOVA (p < 0.0001). Bonferroni
post hoc test signiﬁcance is depicted with asterisks, error bars represent
SEM. 0, 3, 4, and 5 DPC n = 4, 4, 5, and 9 for WT and 4, 4, 1, and 3 for
CRR immunized mice respectively. (F) Viremia of pVD1-WT vaccinated
mice increased rapidly 3–5 days after DENV-2 S221 challenge, whereas
pVD1-CRR vaccinated mice had 30-fold, 40-fold, and at least 1800-fold
lower viremia 3, 4, and 5 DPC (all CRR mice <10 FFU/mL) than did WT
immunized mice. Virus titers were log10 transformed and the transformed
data analyzed by two-way ANOVA (p < 0.0001). Bonferroni post hoc test
signiﬁcance is depicted with asterisks, error bars represent SEM. 3, 4, and 5
DPC n = 4, 5, and 6 for WT and 4, 1, and 3 for CRR immunized mice
respectively.
morbidity including decreased activity, coat rufﬂing, and weight
loss. pVD1-WT vaccinated mice suffered from severely enhanced
DENV-2 pathology, including hemorrhagic manifestations pro-
ducing 95%mortality (p< 0.0001 compared to naïve). Conversely,
pVD1-CRR vaccinated mice exhibited reduced DENV-2 disease
enhancement and 68% survival which did not differ from naïve
mouse survival (100%, p = 0.0769) and yet was much greater than
WT vaccinated mouse survival (4.5%, p < 0.0001, the Bonferroni
multiple comparison adjusted α = 0.017; Figure 3D). Sick mice
began exhibiting external signs of morbidity late on day 3 and
reached terminal endpoints 4.5–5.5 DPC for both groups with
one WT vaccinated mouse surviving to 8 DPC.
To characterize which humoral immune determinates might
be responsible for the reduced disease severity and mortality of
CRR vaccinated mice we examined sera from 3, 4, and 5 DPC.
Four animals in each vaccine treatment were selected a priori for
sacriﬁce 3 DPC, a time point when mice exhibited no outward
signs of morbidity. Four and 5 DPC sera were obtained from
terminally sick mice via cardiac puncture just prior to euthana-
sia. Thus, sample sizes were limited on some of these days for
pVD1-CRR vaccinated mice since there was limited mortality
relative to pVD1-WT vaccinated mice. Serum specimens were
collected and DENV-2 Nt50, viremia, and ES-ELISA titers were
determined. DENV-2 neutralization was strongly correlated with
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survival; pVD1-CRR immunized mice exhibited a rapid, large
magnitude rise in DENV-2 neutralization whereas in pVD1-WT
immunized mice, neutralization was lower and increased more
slowly (p < 0.0001 in a two-way ANOVA, Figure 3E). Three DPC
Nt50 titers of pVD1-CRR vaccinated mice were nearly 100 times
greater than those of pVD1-WT vaccinated mice (CRR = 2783.6,
WT = 29.5; Bonferroni post hoc test p< 0.001). This was a>100-
fold increase inDENV-2 neutralization compared to pre-challenge
for CRR vaccinated mice whereas it was a twofold decrease over
the same time period for WT vaccinated mice. Nt50 titers of CRR
vaccinated mice remained high 4 and 5 DPC whereas those of
WT vaccinated mice slowly increased and remained twofold lower
than CRR vaccinated mice by 5 DPC. Viremia was negatively cor-
related with DENV-2 neutralization and positively correlated with
mortality (Figure 3F). 3 DPC mean viremia of WT vaccinated
mice was 33 times higher (2325 FFU/mL) than that of CRR vac-
cinated mice (70 FFU/mL; Bonferroni post hoc test p < 0.001)
with two of four CRR immunized mouse sera below the lim-
its of assay detection (10 FFU/mL). WT viremia continued to
increase 4–5 DPC and by 5 DPC was at least 1800 times higher
than for CRR immunized mice where all individuals had dropped
to below detectable levels (ave = 1.8 × 104 and <10 FFU/mL for
WT and CRR immunized mice respectively; p < 0.001 with Bon-
ferroni post hoc test in two-way ANOVA). These ﬁndings imply
that even though some CRR vaccinated mice were terminally
ill 5 DPC, they had cleared their viremia, whereas WT vacci-
nated mice still exhibited increasing viremia during this time of
maximal mortality. Thus, the rapid, large magnitude increase in
DENV-2 neutralization of pVD1-CRR vaccinated mice was con-
sistent with an anamnestic response and/or potentially redirected
immunity, whereas the slow rise in DENV-2 neutralization of WT
vaccinated mice was more characteristic of a primary immune
response.
pVD1-WT vaccinated AG129 mice suffering from lethally
enhanced DENV-2 disease exhibited pathology consistent with
ADE disease described in passive transfer studies with this mouse
model (Balsitis et al., 2010; Zellweger et al., 2010). 3 DPC neither
vaccinated nor naïve mice exhibited visible pathological symp-
toms upon necropsy. All terminally ill mice however had pale,
blood-depleted livers, increased intestinal capillary bloodﬂow, and
enlarged gaseous stomachs, symptomatic of ﬂuid accumulation
caused by vascular leakage. Only WT vaccinated mice exhib-
ited the most severe gastrointestinal hemorrhage (Figure 4A).
Although gross pathology upon necropsy of vaccinated mice
was not observed until 4 DPC, H&E staining of liver tissue
revealed hepatitis pathology 3 DPC with increasing severity 4 and
5 DPC. Consistent with the reduced gross morbidity and mor-
tality of pVD1-CRR compared to pVD1-WT vaccinated mice,
CRR vaccinated mice reaching terminal endpoints exhibited mild
lymphoplasmacytic portal, multifocal suppurative, and necro-
tizing hepatitis, including vacuolar vein congestion. However,
pVD1-WT vaccinated mice exhibited moderate to severe lympho-
plasmacytic, necrotizing, and multifocal portal hepatitis and in
some individuals extensive vascular thrombosis and advanced vac-
uolar degeneration (Figure 4B). Severe DENV pathology via ADE
posits that there should be increased infection of FcγR bearing
monocytic cells in humans (Morens, 1994) and in AG129 mice,
FIGURE 4 | Pathophysiology of enhanced DENV disease in vaccinated
AG129 mice. (A) Enhanced DENV disease associated vascular leak
pathology of pVD1-WT and -CRR vaccinated mice following sub-lethal
heterologous DENV-2 infection. No pathology was visible in naïve or
vaccinated mice 3 DPC, yet by 4 and 5 DPC mice succumbing to enhanced
disease exhibited severe vascular leakage associated pathology. The same
mouse is shown in the bottom two photos to highlight the severe intestinal
hemorrhage observed in pVD1-WT but not in pVD1-CRR vaccinated mice
(arrows). (B) Histology of uninfected, pVD1-WT, and pVD1-CRR vaccinated
mouse livers 3 DPC. The top row is hematoxylin and eosin stained liver
sections and the bottom row is immunohistochemistry for DENV-2 NS1
protein of the same individual animals. NS1+ mononuclear inﬂammatory
cells and sinusoidal endothelial cells stain red in their cytoplasm and are
visible (arrows) in liver tissue from vaccinated mice but not uninfected
mice. Multiple sections from multiple animals were examined and single
representatives are shown. All photos were taken at 400x magniﬁcation.
(C) In vitro DENV-2 enhancement by pVD1-WT and pVD1-CRR vaccinated
serum 12 weeks following vaccinations and one day prior to DENV-2
challenge. Consistent with the In vivo results, pVD1-WT vaccinated serum
signiﬁcantly enhanced DENV-2 infection whereas pVD1-CRR vaccinated
serum did not (p = 0.0012). The data are representative of two independent
experiments of 4 pools of 6–7 individual serum specimens for each vaccine
treatment and were analyzed with two-way ANOVA and Bonferroni post
hoc test signiﬁcance at individual dilutions is depicted with asterisks.
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previous studies found that antibody-enhanced mortality was
associated with increased DENV infection and replication in liver
sinusoidal endothelial cells (Balsitis et al., 2010; Zellweger et al.,
2010). To assess viral replication in liver tissue we used immunos-
taining for DENV-2 NS1 protein which is expressed during viral
replication. Of note, although we did not attempt to quantify dif-
ferences between WT and CRR vaccine treatments, mononuclear
inﬂammatory cells in the portal areas and sinusoidal endothe-
lial cells of both WT- and CRR vaccinated liver tissue were NS1
positive by 3 DPC, suggestive of active viral replication in FcγR
bearing cells of the liver, and liver tissue of naïve mice was nega-
tive for NS1 by immunostaining (Figure 4B). Lastly, pre-challenge
pVD1-WT vaccinated mouse serum (1 day prior to DENV-2 chal-
lenge) signiﬁcantly enhancedDENV-2 replication in FcγR bearing
human K562 cells, and pVD1-CRR immunized mouse sera did
not (Figure 4C). In summary, the high levels of DENV-1 vaccine
induced cross-reactive EDIIFP IgG prior to challenge, increased
pathology and mortality, higher viremia, and active viral replica-
tion in FcγRbearing cells ofWT immunizedmice are all consistent
with previous descriptions of antibody-enhanced DENV disease
in AG129 mice (Balsitis et al., 2010; Zellweger et al., 2010).
Cross-reactivity reduced DNA vaccination sculpts immune memory
so that response to virus infection is redirected: reducing
pathological and increasing protective immunity
We used DENV-1 and DENV-2 ES-ELISA to quantify and dif-
ferentiate humoral immune responses to DENV-1 vaccination
from DENV-2 challenge. Supporting the hypothesis that WT vac-
cinated mice were slower to mount DENV-2 speciﬁc immunity
due to DENV-1 primed cross-reactive memory responses, WT
vaccinated mice had lower DENV-2 total IgG titers yet larger
populations of both DENV-1 and DENV-2 EDIIFP IgG than did
CRR vaccinatedmice following heterologous challenge (Figure 5).
Total DENV-1 IgG titers did not differ between vaccine treat-
ments 3, 4, and 5 DPC with DENV-2 (Figure 5A); however,
DENV-2 IgG titers were higher for pVD1-CRR than for pVD1-WT
immunizedmice (Figure 5B). Nevertheless, pVD1-WTvaccinated
mice had signiﬁcantly larger populations of EDIIFP IgG for both
DENV-1 (Figure 5C) and DENV-2 (Figure 5D) than did pVD1-
CRR vaccinated mice. Not only did pVD1-WT mice have larger
populations of cross-reactive EDIIFP IgG following heterologous
challenge, there was also a signiﬁcant increase in DENV-1 EDIIFP
IgG post challenge when compared to the 12 week pre-challenge
data (Figure 5C). DENV-1 EDIIFP IgG GMT of WT immunized
mice increased from 17.7 ± 4.6% pre-challenge to 35.5 ± 5.4%
of the total IgG response post DENV-2 challenge. However, there
was no increase in DENV-1 EDIIFP IgG for CRR immunized mice
before and after challenge (p = 0.364, Mann–Whitney U). We
also analyzed individual pairs of pre- and post-DENV-2 challenge
sera from WT immunized mice for DENV-1 EDIIFP IgG and this
analysis also demonstrated a signiﬁcant increase post-challenge
(p = 0.0138) and a signiﬁcant effect of individual serum pairing
(p = 0.0267, one-tailed paired t-test; data not shown). Together,
these results suggest a strong memory response to cross-reactive E
protein epitopes in DENV-2 that were primed by pVD1-WT vac-
cination and that such an immunodominant anamnestic response
was lacking in pVD1-CRR immunized mice.
ES-ELISA can also determine the proportion of IgG recogniz-
ing E epitopes outside of the manipulated EDIIFP and EDIIICR
antigenic regions in the pVD1-CRR vaccine (non-EDIIFPEDIIICR
IgG; Figure 1;Hughes et al., 2012a). We hypothesized that pVD1-
CRR immunizedmice,with their reducedEDIIFP response, should
exhibit increased capacity to redirect humoral immune responses
to increase the DENV-2 non-EDIIFPEDIIICR antibody popula-
tions concomitant with their reduced EDIIFP response and that
WT immunized mice should show the opposite pattern. Support-
ing this prediction, CRR vaccinated mice had signiﬁcantly larger
populations of DENV-2 non-EDIIFPEDIIICR IgG 3, 4, and 5 DPC
withDENV-2 than did pVD1-WT immunizedmice (p= 0.0025 in
two-way ANOVA; Figure 5E). This was the same time period that
WT immunized mice exhibited maximum enhanced DENV-2 dis-
ease mortality (Figure 3D) and signiﬁcant increases in EDIIFP IgG
(Figures 5C,D); whereas CRR immunized mice exhibited 100-
fold increased DENV-2 neutralization (Figure 3E). Moreover, a
comparison of DENV-1 non-EDIIFPEDIIICR IgG for individual
WT immunized mice pre- and post-challenge showed a signif-
icant decrease (p = 0.0435) in this antibody population 3–5
DPC and a signiﬁcant effect of individual mouse serum pairing
on this decrease (p = 0.0111, one-tailed paired t-test; data not
shown). A decrease in this DENV-1 antibody population of WT
immunized mice is what one would expect if there is a trade-off
between immunodominant secondary responses to EDIIFP and
non-EDIIFPEDIIICR epitopes. Antibody stimulated from epitopes
outside EDIIFP and EDIIICR antigenic regions altered in our
pVD1-CRR vaccine include neutralizing DENV complex reac-
tive antibodies such as MAb 1B7 primed by either vaccine and
boosted byDENV-2 challenge (Table 2) and/orDENV-2 serotype-
speciﬁc neutralizing antibodies stimulated only by the challenge
virus.
Three non-mutually exclusive mechanisms could explain the
rapid increase in DENV-2 neutralizing antibody by CRR immu-
nized mice 3 DPC: (1) anamnestically increased complex cross-
reactive neutralizing antibody not altered by the substitutions
introduced in the pVD1-CRR vaccine (e.g., 1B7-like), (2) pri-
marily increased DENV-2-speciﬁc neutralizing antibody, or (3)
increased relative neutralizing capability of CRR vaccinated sera
by these or other neutralizing antibody populations due to a lack of
steric interference by the large populations of EDIIFP IgG present
inWTvaccinatedmice (Ndifon et al., 2009). To test if the increased
Nt50 titers of CRR vaccinated mice were due to increases in DENV
complex cross-reactive neutralizing antibodies we determined the
Nt50 titers for CRR and WT vaccinated mouse serum 3 DPC
against DENV-1, DENV-3, and DENV-4 (Figure 5F). The mean
(n = 4 each) Nt50 titers for CRR and WT vaccinated mice respec-
tively were 46 and 33 for DENV-1 (p = 0.066), 55 and 27 for
DENV-3 (p = 0.0009), and 147 and 42 for DENV-4 (p = 0.0178;
one-tailed t-test for all). These 1.5-, 2.0-, and 3.5-fold higher
DENV-1, -3, and -4 Nt50 titers for CRR vaccinated mice did not
approach the nearly 100-fold greater DENV-2 Nt50 titer of CRR
immunized mice 3 DPC (2785 and 29 respectively). These data
suggest that CRR vaccinated mice appear to have increased com-
plex cross-reactive neutralizing antibody relative toWTvaccinated
mice; but this antibody class either neutralizes DENV-2 more efﬁ-
ciently than other DENV serotypes, or there are also increased
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FIGURE 5 | DENV-1 CRR vaccination sculpts immunity to redirect
secondary immunity to heterologous dengue infection. AG129 mice
were immunized (i.m.) with 100 μg of pVD1-WT or pVD1-CRR vaccines and
challenged at 12 weeks with heterologous DENV-2 S221 (4.2x105 FFU, i.p.).
Arithmetic means and SEM are depicted in A, B, D, and E and analyzed with
two-way ANOVA. Bonferroni post hoc test signiﬁcance is depicted with
asterisks. (A) DENV-1 total IgG endpoint titers of pVD1-WT and -CRR
immunized mice 3, 4, and 5 DPC with DENV-2. Three, 4, and 5 DPC n = 4, 3,
and 8 and 4, 1, and 3 for WT and CRR vaccines respectively. (B) DENV-2 total
IgG endpoint titers of pVD1-WT and -CRR vaccinated mice. (C) Percent
DENV-1 epitope-speciﬁc responses pre- and post-challenge for IgG
recognizing immunodominant cross-reactive EDIIFP epitopes. pVD1-WT
immunized mice had larger populations of EDIIFP post DENV-2 challenge
than did pVD1-CRR immunized mice (ave = 35.5 and 7.65%, respectively,
p = 0.0004). pVD1-WT immunized mice also exhibited an increase in EDIIFP
IgG from pre- to post-DENV-2 challenge (ave = 17.7 and 35.5%, respectively,
p = 0.0057. Geometric means and 95% CI are depicted. Statistical
signiﬁcance was determined with a one-tailed Mann–Whitney U. The
Bonferroni α = 0.025. (D,E) DENV-2 epitope speciﬁc IgG responses post
DENV-2 challenge of pVD1-WT and pVD1-CRR immunized AG129 mice; 3, 4,
and 5 DPC n = 4, 5, and 9 and 4, 1, and 2 for WT and CRR immunized mice
respectively. (D) Percent DENV-2 IgG recognizing immunodominant
cross-reactive EDIIFP epitopes. (E) Percent DENV-2 IgG recognizing E protein
epitopes outside of immunodominant EDIIFP and EDIIICR antigenic regions
(Non-EDIIFPEDIIICR). (F) FRμNT50 titers of pVD1-WT and -CRR immunized
mouse sera 3 DPC with DENV-2 against DENV-1, DENV-2, DENV-3, and
DENV-4. Bars represent GMT, statistical signiﬁcance was determined with
a one-tailed t -test. All titers were log10 transformed prior to analysis.
proportions of DENV-2 speciﬁc neutralizing antibody in CRR
vaccinated serum by 3 DPC with DENV-2.
To further characterize the epitopes recognized by the anti-
bodies responsible for the rapid rise in DENV-2 neutralization
observed in CRR vaccinated mice, we tested the ability of 3
DPC sera to block the binding of labeled MAbs in a DENV-
2 epitope-blocking ELISA. We examined the blocking by WT
and CRR vaccinated mouse sera for MAbs recognizing com-
plex cross-reactive epitopes present in both DENV-1 vaccines
and in the DENV-2 challenge virus (1B7, 10-D35A, and D3-
5C9-1), MAbs recognizing sub-complex cross-reactive epitopes
knocked out in the CRR vaccine but present in the WT vaccine
and DENV-2 challenge virus (1A1D-2 and 9D12), and MAbs
recognizing DENV-2 serotype-speciﬁc epitopes present only in
the challenge virus (9A3D-8 and 3H5). Surprisingly, pVD1-CRR
vaccinated mouse sera exhibited signiﬁcantly greater blocking
than did WT vaccinated sera for all of these MAbs with the
exception of D3-5C9-1 the only non-neutralizing MAb against
DENV-2, implying that CRR immunized mice had higher titers
of antibody recognizing the same or similar epitopes as these
labeled MAbs (Figure 6). The greatest relative increase in blocking
was for DENV complex, neutralizing MAb 1B7 which exhib-
ited 16-fold greater blocking by CRR than the 2.25% blocking
by WT (p = 0.0072, two-tailed t-test), implying greater 1B7-
like neutralizing antibody in CRR vaccinated mouse sera than
in WT mouse sera, and consistent with increased anamnestic
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FIGURE 6 | DENV-1 CRR vaccination redirects immune responses to
DENV-2 to increase a diversity of neutralizing antibodies. Percent blocking
of labeled monoclonal antibodies (MAbs) by pVD1-WT and pVD1-CRR
immunized mice 3 DPC to DENV-2 as determined by blocking ELISA. AG129
mice were immunized (i.m.) with 100 μg of pVD1-WT or pVD1-CRR vaccines
and challenged at 12 weeks with a sub-lethal dose of heterologous DENV-2
S221 (4.2 × 105 FFU, i.p.). 3 DPC sera of the four mice from each vaccine
treatment were pooled and percent blocking was determined independently
four times in duplicate. To facilitate comparison between vaccine treatments
across the different MAbs, x-fold increases in blocking by pVD1-CRR
vaccinated sera relative to pVD1-WT vaccinated sera are depicted above the
x -axis for each MAb. Below the MAbs, serotype speciﬁcity is depicted
(DENV-2, DENV-2 type-speciﬁc; subcomp, DENV sub-complex cross-reactive;
complex, DENV complex cross-reactive and complex + supercomplex
cross-reactive). Below speciﬁcity, p-values from a two-tailed t test comparing
percent blocking for each vaccinated sera are depicted. Below that the
presence or absence of the epitope recognized by each MAb on the DENV-1
CRR VLP antigen is depicted (all MAbs recognize epitopes found in the
DENV-2 challenge virus). For example, 3H5 and 9A3D-8 as DENV-2 speciﬁc
antibodies are absent on both pVD1-WT and pVD1-CRR VLP antigens; 9D12
and 1A1D-2 reactivity are ablated by the EDIIICR substitutions in the
pVD1-CRR plasmid (Table 2) but present in the WT DENV-1 antigen; and
10-D35A, D3-5C9-1, and 1B7 reactivities were not altered by the substitutions
introduced into in the pVD1-CRR plasmid and hence are present on both
DENV-1 WT and CRR immunization antigens. FRμNT50 titers for each MAb
against DENV-2, -1, -3, and -4 in μg/mL are also shown.
induction of normally sub-dominant 1B7-like antibody in CRR
immunized mice. CRR vaccinated mice also had 3.7 and 1.6-fold
larger populations of DENV-2 serotype-speciﬁc potently neutral-
izing 3H5 and 9A3D-8 like antibodies than did WT vaccinated
mice (p = 0.0003 and p = 0.0058, respectively), 2.4- and 2-
fold greater sub-complex cross-reactive neutralizing 1A1D-2 and
9D12 like antibodies (p = 0.0001 and p < 0.0001 respectively),
and 3.1-fold more DENV complex cross-reactive weakly neu-
tralizing 10-D35A like antibodies (p = 0.0026). There was a
non-signiﬁcant 2.1-fold increase in complex cross-reactive MAb
D3-5C9-1. We next determined the neutralizing capabilities of
these sevenMAbs sincenot all hadbeenpreviously published in the
literature (Figure 6). Not surprisingly, DENV-2 serotype-speciﬁc
MAbs 3H5 and 9A3D-8 exhibited potent DENV-2 neutraliza-
tion (Nt50 = 0.15 and 0.94 μg/mL respectively). 1A1D-2 also
potently neutralized DENV-2 (0.46 μg/mL) although it neutral-
ized DENV-1 and DENV-3 about threefold less than DENV-2,
similar to the DENV-2 neutralizing capabilities of both 9D12
and 1B7. 10-D35A exhibited weak neutralization of DENV-2
(13.04 μg/mL), and D3-5C9-1 did not neutralize any DENV
serotype. Together, these results begin to tease apart the individ-
ual humoral immune components responsible for the polyclonal
response of vaccinated mice to heterologous infection. The 100-
fold increase in DENV-2 neutralization appeared to be due
to a combination of large increases in cross-reactive neutral-
izing antibodies, similar to 1B7, but also to relative increases
and large populations of potently neutralizing serotype-speciﬁc
and sub-complex cross-reactive antibodies. Thus, in response to
heterologous DENV-2 infection, pVD1-CRR immunized mice
exhibited rapid increases in neutralizing antibody populations
with diverse patterns of reactivity that not only increased pro-
tection from enhanced DENV-2 disease mortality but also
exhibited increased neutralization breadth across the DENV
complex.
Frontiers in Immunology | Microbial Immunology November 2012 | Volume 3 | Article 334 | 14
“ﬁmmu-03-00334” — 2012/11/6 — 22:00 — page 15 — #15
Crill et al. Redirecting dengue immune responses
DISCUSSION
In this report we constructed WT and CRR DENV-1 DNA
vaccine candidates and compare their humoral immunogenic-
ity as it relates to vaccine safety and efﬁcacy using the AG129
mouse dengue disease model. The CRR vaccine was speciﬁcally
engineered as a second generation vaccine candidate to reduce
the potential for vaccine-induced susceptibility to severe dengue
disease via ADE, a theoretical safety concern for dengue vac-
cine development (Miller, 2010; Murphy and Whitehead, 2011;
Thomas, 2011; Heinz and Stiasny, 2012). CRR immunized mice
had signiﬁcantly reduced titers of EDIIFP antibodies, induced
from cross-reactive immunodominant epitopes associated with
ADE and increased pathology in humans and dengue animal
models (Goncalvez et al., 2007; Balsitis et al., 2010; Beltramello
et al., 2010; Dejnirattisai et al., 2010; Zellweger et al., 2010). We
further demonstrate that by disrupting these epitopes we can
redirect the immunodominance hierarchy away from pathogenic
toward normally subdominant, potently neutralizing epitopes.
WTvaccinatedmice hadhighEDIIFP antibody titers and enhanced
a heterologous, sub-lethal DENV-2 infection into a DHF-like
disease pathology resulting in 95% mortality. CRR vaccinated
mice however, lacking measurable EDIIFP antibodies, exhibited
increased protective, neutralizing immunoglobulins, and had sig-
niﬁcantly reducedmorbidity andmortality that did not differ from
naive mice.
The location of E protein substitutions introduced into the
pVD1-CRR vaccine construct used in this study was based upon
previously published work in DENV-2 (Crill et al., 2009; Hughes
et al., 2012a). We previously constructed DENV-2 CRR DNA vac-
cines with substitutions knocking out cross-reactive epitopes in
the EDIIFP, in EDIII, and in both EDIIFP and EDIII and com-
pared their immunogenicity with each other and with the WT
DENV-2 vaccine (Hughes et al., 2012a). All vaccines induced sim-
ilar high-titer DENV-2 neutralizing antibody responses in Swiss
Webster mice. In in vitro ADE assays, sera from WT immunized
mice signiﬁcantly enhanced DENV-1, -2, and -3 replication and
sera from mice immunized with EDIIFP or EDIII substitutions
enhanced DENV-1 or DENV-3, only serum from mice immu-
nized with vaccines containing CRR substitutions in both EDIIFP
and EDIII lacked enhancing capabilities for all serotypes at the
lowest tested serum dilution (1:2). We observed that vaccines con-
taining substitutions in EDIII exhibited a non-signiﬁcant trend
toward reduced DENV-2 neutralizing antibody titers but that
the vaccine containing substitutions in both EDIIFP and EDIII
also showed the greatest increase in heterologous neutralization.
Based upon these observations we decided to incorporate substi-
tutions in both EDIIFP and EDIII into the DENV-1 CRR vaccine
construct.
Our results, suggestive of vaccine-induced severe dengue dis-
ease and mortality via ADE, are consistent with and supported
by two recent studies of ADE-induced dengue disease in AG129
mice using passive transfer of DENV immune sera (Balsitis et al.,
2010; Zellweger et al., 2010). These studies found that administer-
ing 104, 105, or 106 pfu of DENV-2 S221 was sub-lethal to naïve
AG129 mice receiving passively transferred normal mouse serum
24 h prior to challenge. However, mice receiving heterologous
DENV-1, -3, or -4 immune sera 24 hr prior to challenge died
4–5 DPC from severe dengue disease resembling DHF. The disease
pathology was similar to that seen in human DHF. Conﬁrmation
that this enhanced DHF-like disease and mortality resulted from
ADE was supported by passive transfer of enhancing EDIIFP MAb
4G2 and by rescue from enhanced mortality by passive transfer of
4G2 F(ab′)2 fragment unable to bind FcγR (Balsitis et al., 2010).
In this study, we found that when exposed to normally sub-lethal
doses of DENV-2 S221, pVD1-WT vaccinated mice suffered 95%
mortality, shared many of these same symptoms and that the high
viremia and enhanced disease pathology and mortality were sig-
niﬁcantly reduced by immunization with a modiﬁed pVD1-CRR
vaccine.
An important ﬁnding in this study was the rapid induction
of diverse DENV-2 neutralizing antibodies by pVD1-CRR vacci-
nated mice in response to heterologous DENV-2 infection. There
was a large increase in 1B7-like antibody for CRR vaccinated mice,
supporting the importance of this class of neutralizing antibody.
However, the majority of the increase in DENV-2 neutraliza-
tion by CRR vaccinated mice appeared to be due to DENV-2
serotype-speciﬁc neutralizing antibody, since DENV-1, -3, and -4
neutralization only increased moderately. Neither pVD1-WT nor
pVD1-CRR immunized mice were primed for DENV-2 serotype-
speciﬁc neutralizing antibody responses, how then could this
antibody class be so potently increased during early acute het-
erologous DENV-2 infection in CRR immunized mice? A recent
study examining humoral and cellular immune response to pri-
mary DENV-1 and secondary DENV-2 infections in AG129 mice
is relevant to this discussion (Zompi et al., 2012). These authors
observed that by 6 days post-infection naïve B cells had differenti-
ated into plasma cells capable of producing both serotype-speciﬁc
and cross-reactive neutralizing antibody. Notably though, DENV-
2-speciﬁc plasma cells peaked at 6 days post-primary DENV-2
infection, but in secondary DENV-2 infected mice this peak was
delayed until 9 days post-infection. These ﬁndings were inter-
preted to suggest that secondarily infecting DENV-2 antigen was
more readily captured by cross-reactive DENV-1 derived memory
B cells and/or antibody, preventing the early binding and activa-
tion of naïve B cells during secondary DENV-2 infection. A similar
phenomenon could explain themore rapid productionof DENV-2
serotype-speciﬁc neutralizing antibody in pVD1-CRR immunized
mice by 3 DPC with DENV-2. We believe such a process to be a
major mechanistic explanation behind the immune redirection
associated with the reduced DENV-2 disease enhancement and
mortality observed in pVD1-CRR immunized mice.
A surprising ﬁnding was the rapid increase of sub-complex
cross-reactive antibodies in pVD1-CRR immunized mice fol-
lowing DENV-2 infection, since antibodies recognizing epitopes
similar to MAbs 1A1D-2 and 9D12 should have been primed by
pVD1-WTbutnot bypVD1-CRRvaccination. Onepossible expla-
nation is that the CRR substitutions introduced into EDIII did
not completely knock-out these epitopes. This is possible because
EDIIICR antibodies recognize epitopes in a complex, conforma-
tional antigenic surface (Sukupolvi-Petty et al., 2007; Gromowski
et al., 2008; Pierson et al., 2008; Cockburn et al., 2012). However,
the increased production of sub-complex cross-reactive antibod-
ies in CRR vs. WT vaccinated mice may simply be due to a reduced
capability of WT vaccinated mice to produce this sub-dominant
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antibody class in response to DENV-2 infection (Zompi et al.,
2012). This study did not address the possible role of antibody
interference in explaining the rapid increases in DENV-2 neu-
tralization observed in pVD1-CRR vaccinated mice (Ndifon et al.,
2009). Weakly or non-neutralizing antibodies recognizing EDIIFP
epitopes could sterically interfere with the binding of potently
neutralizing antibodies recognizing either EDIII or recently iden-
tiﬁed inter-dimer quaternary epitopes (de Alwis et al., 2012). The
lack of large populations of EDIIFP IgG in pVD1-CRR vaccinated
mouse serum can therefore increase its relative neutralization and
we suspect this phenomenon to also play a role in the increased
neutralization of pVD1-CRR vaccinated mice.
Because this study utilized active vaccination, the increased
survival and decreased disease incidence and severity of pVD1-
CRR vaccinated mice could result from additional factors such as
differences in cellular immunity. Even in IFNα/β, IFNγ receptor-
deﬁcient AG129 mice, cellular immunity could play an important
role in either protection from or enhancement of dengue infec-
tion and disease (Yauch et al., 2009, 2010; Zompi et al., 2012). As
a part of a recently published CD4+ T cell study we developed an
overlapping peptide library for DENV-2 prM and E proteins. Mice
immunized with DENV-2 CRR vaccines, containing substitutions
at the same EDIIFP and EDIIICR residues, did not differ in CD4+
or CD8+ T cell recognition for the WT DENV-2 peptides, imply-
ing that the substitutions introduced into DENV CRR vaccines
are either not located in T cell epitopes or do not alter existing T
cell epitopes in these regions (Hughes et al., 2012b; Hughes and
Chang, unpublished data).
Most immunodominant DENV T cell epitopes have been local-
ized to the non-structural proteins, particularly NS3, and theDNA
vaccines utilized in this study do not contain the genes coding
for non-structural proteins (Mathew and Rothman, 2008). T cell
epitopes that have been localized to the prM/E structural pro-
teins have predominately been localized to regions outside those
modiﬁed in our CRR vaccine (Yauch et al., 2009; Duangchinda
et al., 2010). Roehrig et al. (1994) found that a DENV-2 E protein
peptide containing EDIIFP residues did not induce virus-reactive
CD4+ T cells in vitro or prime H-2b CD4+ virus-speciﬁc T cells
whereas peptides spanning EDIII residues 302–333 or 352–368
could weakly induce such priming. It is therefore possible that
pVD1-CRR substitutions could increase CD4+ T cell priming
beyond the low levels observed with the WT peptides to boost
humoral immunity or that the EDIIFP and/or EDIIICR substitu-
tions could increase CD8+T cell activation relative toWTvaccine;
possibly accounting for the observed survival differences. How-
ever, similar pathologies were observed following passive transfer
of DENV immune sera (Balsitis et al., 2010; Zellweger et al., 2010).
In the present study, we observed in vitro DENV-2 enhancement
with pVD1-WT vaccinated mouse sera that was not observed with
pVD1-CRR vaccinated sera; and in our recently published study,
enhanced disease mortality of AG129 mice was similarly reduced
following passive transfer of DENV-2 CRR vaccinated mouse sera
(Hughes et al., 2012a). Together, these ﬁndings support the inter-
pretation that the enhancedDHF-like disease andmortality of WT
immunized mice and its signiﬁcant reduction in pVD1-CRR vac-
cinated mice, was most likely due to the observed alterations of
humoral immunity.
The pVD1-CRR vaccine exhibited an improved safety proﬁle
compared to WT in an in vivo AG129 model, however, some CRR
vaccinated mice still succumbed to DENV disease, implying either
that there could be additional pathogenic antibody classes not tar-
geted by our CRR modiﬁcations or that mechanisms in addition
to ADE may have been responsible for the mortality observed
in pVD1-CRR vaccinated mice. Cross-reactive, non-neutralizing
antibody recognizing prM has recently been reported to com-
prise a signiﬁcant portion of the human anti-DENV response
and such antibody can enhance DENV replication (Beltramello
et al., 2010; Dejnirattisai et al., 2010; Rodenhuis-Zybert et al.,
2010). However, the limited data suggest that prM antibodies
may not be as frequently induced in mice as in humans (Hen-
chal et al., 1985; Roehrig et al., 1998); this could be the result of
different routes of infection, needle (i.m.) versus mosquito (i.d.)
or of the different forms of virus (mature, immature, or par-
tially mature) being delivered. Nevertheless, VLPs produced by
our ﬂavivirus and DENV plasmids in tissue culture do contain
prM and vaccination with these plasmids can produce antibody
recognizing prM (Chang et al., 2003; Chiou et al., 2012). CRR
substitutions introduced into these plasmids do not alter the
prM processing or change the relative ratios of VLP prM and
E or their induced antibody populations in comparison to WT
(Chiou et al., 2012). Thus, prM antibodies may be of concern in
human vaccination and they could explain the residual enhance-
ment observed in CRR vaccinated AG129 mice (Henchal et al.,
1985; Roehrig et al., 1998), but they are unlikely to account for
the differences in pathology and mortality between pVD1-CRR
and -WT immunized mice in this study. Alternatively, residual
CRR vaccinated mouse enhancement could have occurred via
antibody recognizing E protein epitopes outside of the CRR mod-
iﬁcations and/or from lower, non-protective levels of normally
protective antibodies (Pierson et al., 2008; Beltramello et al., 2010;
Hughes et al., 2012a).
Antibody-mediated neutralization and enhancement are two
phenomena that exist along a continuum of antibody concen-
tration. Antibody-mediated neutralization of ﬂaviviruses requires
virion loadingwith a stoichiometry that exceeds the neutralization
threshold. This neutralization threshold varies for different anti-
bodies based upon their afﬁnity and epitope accessibility. When
antibody occupancy does not exceed this neutralization threshold,
enhancement can occur (Pierson et al., 2008). EDIIFP epitopes
are relatively inaccessible on mature and partially mature virions
and antibodies recognizing these epitopes typically require high to
saturated occupancy if they are to neutralize virus at all. Such anti-
bodies therefore have the potential to enhance infection across a
wide range of concentrations. Serotype-speciﬁc potently neutral-
izing antibodies recognizing EDIII lateral ridge epitopes such as
DENV-2 speciﬁc 3H5 and 9A3D-8 however, are able to neutralize
virus at much lower occupancy thresholds (Pierson et al., 2008).
The implication of these ﬁndings is that antibody recognizing
EDIIFP epitopes will tend to enhance infection at most concen-
trations and only neutralize at very high concentrations whereas
EDIII serotype-speciﬁc antibodies will neutralize acrossmost con-
centrations and only enhance at the lowest concentrations. Thus,
the reduced levels of cross-reactive EDIIFP recognizing antibody
and increased levels of DENV-2 speciﬁc antibody in pVD1-CRR
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immunized mice supports their playing important roles in the
observed differences in morbidity and mortality.
The concern of vaccine-induced immunodominant antibody
responses in dengue vaccinology and our approach of genetically
modifying these pathogenic epitopes to redirect the immunodom-
inance hierarchy have parallels with other multi-strain pathogens
such as HIV and Inﬂuenza. Both HIV and inﬂuenza vaccinology
have to address original antigenic sin and strain-speciﬁc immun-
odominance. For all of these viruses, producing efﬁcacious and
improved next-generation vaccines is likely to require altering
the native, WT immune responses (Ndifon et al., 2009; Miller,
2010; Durbin and Whitehead, 2011; Nara et al., 2011; Schmitz
et al., 2011). In both HIV and inﬂuenza there has been interest in
this area of modifying immunogens to redirect immune responses,
typically referred to as immune dampening and immune refocus-
ing. Some generalizations from this body of work are consistent
with and support our CRR DENV DNA vaccination results. The
dampening of immunodominant epitopes resulted in decreased
induction of antibodies recognizing the targeted epitopes while
increasing the amount of antibody stimulated from natively sub-
dominant epitopes. Moreover, in spite of such major alterations in
immunodominance hierarchies, antigenically modiﬁed immuno-
gens induced similar total overall antibody titers as did WT
immunogens (Tobin et al., 2008).
There is substantial interest in utilizing heterologous vaccine
prime-boost strategies to improve and broaden immunogenicity,
especially in the context of DNA vaccination (Dale et al., 2006;
Chen et al., 2007; Simmons et al., 2010; Ding et al., 2011; Guenaga
et al., 2011). In this context, “heterologous” typically refers to the
use of different vaccine formats to present the same viral immuno-
gens between prime and boost, most commonly DNA prime and
protein (recombinant, inactivated virus, or live attenuated virus)
boost. Much of this interest has also been directed toward HIV
(Walker and Burton, 2010) and inﬂuenza (Wei et al., 2010; Ding
et al., 2011) where the vaccine goal is to increase the breadth of
neutralization and hence protection from these highly variable
multi-strain pathogens. Because of the similarities to DENV and
the difﬁculties of rapidly inducing balanced tetravalent immu-
nity with current DENV live-attenuated vaccines (Guy et al., 2009;
Murphy and Whitehead, 2011), DNA prime-protein boost strate-
gies are particularly appealing to DENV vaccinology. We found
thatDENV-1CRRDNAvaccination redirected subsequent immu-
nity in response to DENV-2 challenge and increased the induction
of a broad repertoire of neutralizing antibodies to produce a
polyclonal DENV-2 neutralizing response with increased cross-
neutralization to other DENV serotypes. Our ﬁndings suggest
that CRR DNA vaccines hold potential for novel DENV vaccine
strategies that take advantage of the beneﬁts of both DNA and
live attenuated virus vaccines. One such strategy is to prime hosts
with a low-dose tetravalent CRR DNA vaccine to elicit a beneﬁcial
memory response with reduced enhancing capability and limited
neutralizing antibody to each serotype. Such priming might allow
for efﬁcient tetravalent live-attenuated virus boost 1–2 months
later to produce balanced and protective tetravalent immunity.
We are currently initiating preclinical studies using this strategy
with the goal to achieve protective tetravalent immunity within
3 months; a long sought after goal of DENV vaccinology that
continues to elude existing DENV vaccine candidates.
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